Insider Trading History of Harshbarger Benjamin

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Harshbarger Benjamin since 2016. The trader's CIK number is 1653133. At the time of the last reporting, Harshbarger Benjamin was the General Counsel of Novelion Therapeutics Inc.. (stock ticker symbol NVLNF). Also see all insider trading activities at Novelion Therapeutics Inc..

Note that in the past Harshbarger Benjamin also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Novelion Therapeutics Inc. (NVLN) by Harshbarger Benjamin

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2017 NVLN 0 $0 0 $0 1,956 $0

Yearly summary of insider trading at Aegerion Pharmaceuticals, Inc. (AEGR) by Harshbarger Benjamin

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2016 AEGR 0 $0 0 $0 2,509 $0


Insider trading activities at 2 companies by Harshbarger Benjamin:

1. Novelion Therapeutics Inc. (NVLN)

2. Aegerion Pharmaceuticals, Inc. (AEGR)

Table 1. Insider trading of Novelion Therapeutics Inc. (NVLN) by Harshbarger Benjamin

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2017-09-17 NVLN Option Ex 337 .00 0
2017-05-15 NVLN Option Ex 717 .00 0
2017-05-09 NVLN Option Ex 724 .00 0
2017-04-01 NVLN Option Ex 178 .00 0

Table 2. Insider trading of Aegerion Pharmaceuticals, Inc. (AEGR) by Harshbarger Benjamin

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2016-04-01 AEGR Option Ex 867 .00 0
2016-09-17 AEGR Option Ex 1,642 .00 0

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Harshbarger Benjamin (General Counsel of Novelion Therapeutics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.